Literature DB >> 17563748

HIF-2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites.

A Le Bras1, F Lionneton, V Mattot, E Lelièvre, B Caetano, N Spruyt, F Soncin.   

Abstract

The mechanisms that are responsible for the restricted pattern of expression of the VE-cadherin gene in endothelial cells are not clearly understood. Regulation of expression is under the control of an approximately 140 bp proximal promoter that provides basal, non-endothelial specific expression. A larger region contained within the 2.5 kb genomic DNA sequence located ahead of the transcription start is involved in the specific expression of the gene in endothelial cells. We show here that the VE-cadherin promoter contains several putative hypoxia response elements (HRE) which are able to bind endothelial nuclear factors under normoxia. The VE-cadherin gene is not responsive to hypoxia but hypoxia-inducible factor (HIF)-2alpha specifically activates the promoter while HIF-1alpha does not. The HRE, that are involved in this activity have been identified. Further, we show that HIF-2alpha cooperates with the Ets-1 transcription factor for activation of the VE-cadherin promoter and that this synergy is dependent on the binding of Ets-1 to DNA. This cooperative action of HIF-2alpha with Ets-1 most probably participates to the transcriptional regulation of expression of the gene in endothelial cells. This mechanism may also be involved in the expression of the VE-cadherin gene by tumor cells in the process of vascular mimicry.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17563748     DOI: 10.1038/sj.onc.1210566

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  Kruppel-like factor-4 transcriptionally regulates VE-cadherin expression and endothelial barrier function.

Authors:  Colleen E Cowan; Erin E Kohler; Tracey A Dugan; M Kamran Mirza; Asrar B Malik; Kishore K Wary
Journal:  Circ Res       Date:  2010-08-19       Impact factor: 17.367

2.  Junctional protein regulation by sphingosine kinase 2 contributes to blood-brain barrier protection in hypoxic preconditioning-induced cerebral ischemic tolerance.

Authors:  Bradley K Wacker; Angela B Freie; Jennifer L Perfater; Jeffrey M Gidday
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-08       Impact factor: 6.200

Review 3.  Dysregulated glycolysis as an oncogenic event.

Authors:  Takumi Mikawa; Matilde E LLeonart; Akifumi Takaori-Kondo; Nobuya Inagaki; Masayuki Yokode; Hiroshi Kondoh
Journal:  Cell Mol Life Sci       Date:  2015-01-22       Impact factor: 9.261

Review 4.  Passing the baton: the HIF switch.

Authors:  Mei Yee Koh; Garth Powis
Journal:  Trends Biochem Sci       Date:  2012-07-18       Impact factor: 13.807

Review 5.  Endothelial permeability and VE-cadherin: a wacky comradeship.

Authors:  Julie Gavard
Journal:  Cell Adh Migr       Date:  2013-12-05       Impact factor: 3.405

Review 6.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

7.  Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.

Authors:  Massimiliano Mazzone; Daniela Dettori; Rodrigo Leite de Oliveira; Sonja Loges; Thomas Schmidt; Bart Jonckx; Ya-Min Tian; Anthony A Lanahan; Patrick Pollard; Carmen Ruiz de Almodovar; Frederik De Smet; Stefan Vinckier; Julián Aragonés; Koen Debackere; Aernout Luttun; Sabine Wyns; Benedicte Jordan; Alberto Pisacane; Bernard Gallez; Maria Grazia Lampugnani; Elisabetta Dejana; Michael Simons; Peter Ratcliffe; Patrick Maxwell; Peter Carmeliet
Journal:  Cell       Date:  2009-02-12       Impact factor: 41.582

8.  Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha.

Authors:  Victoria Wang; David A Davis; Ravindra P Veeranna; Muzammel Haque; Robert Yarchoan
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

Review 9.  Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD.

Authors:  Sophie Van Welden; Andrew C Selfridge; Pieter Hindryckx
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-30       Impact factor: 46.802

10.  VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.

Authors:  C M Lee; M M Hickey; C A Sanford; C G McGuire; C L Cowey; M C Simon; W K Rathmell
Journal:  Oncogene       Date:  2009-03-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.